Marek Sochor, Petra Basova, Michal Pesta, Nina Dusilkova, Jiri Bartos, Pavel Burda, Vit Pospisil, Tomas Stopka
DOI: 10.1186/1471-2407-14-448
Klíčová slova: Breast cancer, microRNA, miR-155, miR-19a, miR-181b, miR-24, Let-7a
Anotace:
Background: MicroRNAs (miRs) represent a distinct class of posttranscriptional modulators of gene expressionZobrazit více »
with remarkable stability in sera. Several miRs are oncogenic (oncomiRs) and are deregulated in the pathogenesis
of breast cancer and function to inhibit tumor suppressors. Routine blood monitoring of these circulating
tumor-derived products could be of significant benefit to the diagnosis and relapse detection of early-stage breast
cancer (EBC) patients.
Methods: Aim of this project was to determine expression of miR-155, miR-19a, miR-181b, miR-24, relative to let-7a
in sera of 63 patients with EBC and 21 healthy controls. Longitudinal multivariate data analysis was performed to
stochastically model the serum levels of each of the oncomiRs during disease phases: from diagnosis, after surgery,
and following chemo/radiotherapy. Moreover, this analysis was utilized to evaluate oncomiR levels in EBC patients
subgrouped using current clinical prognostic factors including HER2, Ki-67, and grade III.
Results: EBC patients significantly over-express the oncomiRs at the time of diagnosis. Following surgical resection
the serum levels of miR-155, miR-181b, and miR-24 significantly decreased (p = 1.89e-05, 5.41e-06, and 0.00638,
respectively) whereas the miR-19a decreased significantly after the therapy (p = 0.00869). Furthermore, in case
of high-risk patients serum levels of miR-155, miR-19a, miR-181b, and miR-24 are significantly more abundant
in comparison to low-risk group (p = 0.026, 0.02567, 0.0250, and 0.00990) and show a decreasing trend upon
therapy.
Conclusions: OncomiRs are significantly more abundant in the sera of EBC patients compared to controls at
diagnosis. Differences in oncomiR levels reflecting EBC risk were also observed. Testing the oncomiRs may be
useful for diagnostic purpose and possibly also for relapse detection in follow-up studies of EBC.
Citace: SOCHOR, Marek, Petra BASOVA, Michal PESTA, Nina DUSILKOVA, Jiri BARTOS, Pavel BURDA, Vit POSPISIL a Tomas STOPKA. Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer. Londýn: BioMed Central, 2014, 14(1), 448. ISSN 1471-2407. Dostupné z: doi:10.1186/1471-2407-14-448